Collectively, these studies demonstrate that targeted inhibition of the NLRP3 inflammasome represents a promising therapeutic strategy for the gastric inflammatory disorders investigated in these models, namely gastric ulcer and chronic atrophic gastritis. The gene discussed is NLRP3; the disease is chronic atrophic gastritis.